Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis | Blood | American Society of Hematology
You do not currently have access to this content.
You do not currently have access to this content.
Xenia Parisi, Sanam Loghavi; Acute erythroid leukemia or acute myeloid leukemia with mutated TP53? The battle of phenotype versus genotype. Blood 2025; 145 (7): 784.…
Key PointsAmong patients alive without relapse at day +100, MRD is uncommon but identifies those at increased risk of relapse and worse survival.Most patie
Blood Podcast | Blood | American Society of Hematology Blood Podcast The editors of Blood are pleased to introduce a podcast series, published weekly…
Xenia Parisi, Sanam Loghavi; Acute erythroid leukemia or acute myeloid leukemia with mutated TP53? The battle of phenotype versus genotype. Blood 2025; 145 (7): 784.…
Key Points. First-line axi-cel demonstrated an 86% complete response rate and 3-year PFS rate of 75% in efficacy-evaluable patients with high-risk LBCLNew
Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin B-cell lymphoma that defies cures in most patients. Over the last decade, significa
Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin B-cell lymphoma that defies cures in most patients. Over the last decade, significa
Mantle cell lymphoma is a rare subtype of B-cell Non-Hodgkin-lymphoma which is clinically characterized by its heterogeneous behaviour with courses ranging
Despite many recent therapeutic advances, mantle cell lymphoma (MCL) remains a largely incurable disease. Treatments for patients with relapsed/refractory (R/R)
Blood | 145 | 7 | February 2025